List view / Grid view
We demonstrate the power of waveRAPID in streamlining the kinetic characterisation of large numbers of drug hit compounds, with results comparable to traditional surface plasmon resonance (SPR) and high reproducibility.
In mice and hamsters, therapies made from two antibodies were found to be mostly effective against a range of SARS-CoV-2 variants.
The application of chemical perturbation approaches in phenotypic models is often used to identify protein targets for therapeutic discovery. Increasingly, small molecule fragments which covalently bind to their protein targets are being used to explore the druggable proteome and the resulting fragment‑protein interactions are characterised by chemoproteomic techniques. In this…
The binding specificity and high binding affinity of therapeutic antibodies makes them an ideal therapy for treating a wide range of human disorders. Advancements in antibody technologies have resulted in huge development success along with a boost in novel and improved treatment strategies. However, specific challenges and considerations are faced…
Neutralisation resistance generated by Spike (S) protein mutations in Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) poses a challenge to antibody therapies for COVID-19. Antibody cocktails targeting the S protein receptor binding domain (RBD) are one way to avoid viral neutralisation escape, however only certain antibody combinations are currently effective.…
Within this ebook, find articles on antibodies to combat SARS-CoV-2 and an evaluation of the various therapeutic forms they can take.
Two groups of infant rhesus macaques received one of two potential COVID-19 vaccines, which were shown to elicit high levels of neutralising antibodies.
Dr Björn Frendeus outlines how the growing biology surrounding the inhibitory Fc receptor FcγRIIb defines a target for improving existing and future antibody treatments.
Researchers have shown that the SARS-CoV-2 PLpro cuts human proteins so could potentially cause a range of COVID-19 symptoms.
A new DNA vaccine encoding the SARS-CoV-2 Spike protein has shown promise at protecting mice and hamsters against COVID-19.
Scientists have shown that trapped LC3B protein in brain cells enables Parkinson's disease to spread, presenting a drug target.
Researchers have discovered that blocking TRPC5 activity treated chronic pain in mouse models of various conditions.
Researchers have shown that a protein named aquaporin can disrupt optical development, leading to cataract formation.
A new modelling method could be used as a surveillance tool to monitor emerging infectious SARS-CoV-2 variants, scientists say.
Microfluidic screening technologies have been used to discover a promising antibody candidate against SARS-CoV-2 and the South African variant.
